26 July 2023
26 July 2023
Alphyn is planning to open sites in the US, Canada, Europe and Australia.
The primary endpoints have been met in the AGAVE-201 study of axatilimab in patients with chronic graft-versus-host disease (cGVHD).
Patients in the study will receive a daily dose of the therapy for the first 14 days, and then every other day until day 28.
The Colorado-based biotech has released its quarterly financial statements for Q2 2023.
The primary objective of the study is to assess the effect of obicetrapib on LDL-C levels at day 84.
Advanced stage cancer patients often develop constant, clinically important, symptoms of psychological distress.
Immuron completes first cohort enrolment with Travelen for diarrhoea caused by E.Coli
Both the entities earlier carried out preclinical research of the therapy in a xenograft mouse model.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
